LOS ANGELES–(BUSINESS WIRE)–Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), …
Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force …
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the …
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health …
